Wedbush Raises Price Target on BioMarin Pharma (BMRN) to $139 Following 2Q Results
Tweet Send to a Friend
Wedbush reiterated a Neutral rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), and raised the price target to $139.00 (from $130.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
